AUS
NZ
UK
CA
USA
IND
Highlights
- Insiders purchased AU$949.9k in ATX stock last year.
- Current value now stands at AU$714.9k following a 21% decline.
- Insider ownership is 15% of the company.
Over the last year, insiders at Amplia Therapeutics Limited (ASX:ATX) invested significantly in company shares, buying a total of AU$949.9k at an average price of AU$0.072 per share. Unfortunately, facing a 21% drop in stock value, these shares are now worth about AU$714.9k. While fluctuations in stock value can be expected, it's noteworthy that insiders showed confidence in the company’s prospects by purchasing shares above the current price, now at AU$0.054.
The largest insider acquisition came from Allan Moss, who invested AU$296k at approximately AU$0.055 per share. These transactions indicate a certain level of confidence in the company’s future, despite the short-term setbacks. Generally, stock purchases by insiders at prices higher than current trading levels can be interpreted as a positive signal.
Throughout the past year, insiders have only acquired shares and have refrained from parting with any, reflecting a sense of optimism. With insider ownership standing at 15%, the interests of insiders seem relatively aligned with the company’s long-term goals.
Though there have been no new insider transactions in the last three months, the overall trend over the past year suggests a reassuring level of interest and commitment from inside the company. While the activities don’t show cause for alarm, increased insider holdings would be additionally comforting for stakeholders.
Potential investors need to be mindful of the risks associated with Amplia Therapeutics, as outlined in recent analyses. Understanding insider activities can provide a valuable perspective, but must be balanced with awareness of existing risks and opportunities within the company.
